Thomas Kenneth C, Nosyk Bohdan, Fisher Charles G, Dvorak Marcel, Patchell Roy A, Regine William F, Loblaw Andrew, Bansback Nick, Guh Daphne, Sun Huiying, Anis Aslam
Department of Surgery (Orthopedics), University of Calgary, Calgary, AB, Canada.
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1212-8. doi: 10.1016/j.ijrobp.2006.06.021.
A recent randomized clinical trial has demonstrated that direct decompressive surgery plus radiotherapy was superior to radiotherapy alone for the treatment of metastatic epidural spinal cord compression. The current study compared the cost-effectiveness of the two approaches.
In the original clinical trial, clinical effectiveness was measured by ambulation and survival time until death. In this study, an incremental cost-effectiveness analysis was performed from a societal perspective. Costs related to treatment and posttreatment care were estimated and extended to the lifetime of the cohort. Weibull regression was applied to extrapolate outcomes in the presence of censored clinical effectiveness data.
From a societal perspective, the baseline incremental cost-effectiveness ratio (ICER) was found to be $60 per additional day of ambulation (all costs in 2003 Canadian dollars). Using probabilistic sensitivity analysis, 50% of all generated ICERs were lower than $57, and 95% were lower than $242 per additional day of ambulation. This analysis had a 95% CI of -$72.74 to 309.44, meaning that this intervention ranged from a financial savings of $72.74 to a cost of $309.44 per additional day of ambulation. Using survival as the measure of effectiveness resulted in an ICER of $30,940 per life-year gained.
We found strong evidence that treatment of metastatic epidural spinal cord compression with surgery in addition to radiotherapy is cost-effective both in terms of cost per additional day of ambulation, and cost per life-year gained.
最近一项随机临床试验表明,对于转移性硬膜外脊髓压迫症的治疗,直接减压手术联合放疗优于单纯放疗。本研究比较了这两种治疗方法的成本效益。
在最初的临床试验中,临床疗效通过行走能力和直至死亡的生存时间来衡量。在本研究中,从社会角度进行了增量成本效益分析。估算了与治疗及治疗后护理相关的成本,并将其扩展到队列的生存期。应用威布尔回归在存在删失临床疗效数据的情况下推断结果。
从社会角度来看,基线增量成本效益比(ICER)为每多行走一天60美元(所有成本以2003年加拿大元计)。通过概率敏感性分析,所有生成的ICER中有50%低于57美元,95%低于每多行走一天242美元。该分析的95%置信区间为 -72.74美元至309.44美元,这意味着该干预措施每多行走一天的成本范围从节省72.74美元到花费309.44美元。以生存作为疗效衡量指标时,每获得一个生命年的ICER为30940美元。
我们发现有力证据表明,对于转移性硬膜外脊髓压迫症,手术联合放疗的治疗方法在每多行走一天的成本以及每获得一个生命年的成本方面均具有成本效益。